Allegro Integrin Peptide Therapy is an intravitreal injection designed to treat diseases such as macular degeneration and diabetic macular edema.
Senju will pay Allegro an upfront license fee, a percentage of royalty sales and sales milestone fees in exchange for the right to co-develop and market the peptide therapy in Japan.
More Articles on Ophthalmology:
Anschutz Investment Donates $.15M to Create Ophthalmology Chair at CU
FDA Approves Bausch + Lomb TRULIGN Astigmatism Correction Lens
NIVISON, Avellino Labs Partner to Offer Patients ACD Testing
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
